9C7 Stock Overview
Calmark Sweden AB (publ) operates as a medical technology company in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Calmark Sweden AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0002 |
| 52 Week High | €0.063 |
| 52 Week Low | €0.0002 |
| Beta | 1.49 |
| 11 Month Change | -98.82% |
| 3 Month Change | 0% |
| 1 Year Change | -99.24% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9C7 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.8% |
| 1Y | -99.2% | -5.0% | 9.1% |
Return vs Industry: 9C7 underperformed the German Medical Equipment industry which returned 11.1% over the past year.
Return vs Market: 9C7 underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| 9C7 volatility | |
|---|---|
| 9C7 Average Weekly Movement | 2,933.2% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9C7's share price has been volatile over the past 3 months.
Volatility Over Time: 9C7's weekly volatility has increased from 1642% to 2933% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 4 | Camilla Arneving | www.calmark.se |
Calmark Sweden AB (publ) operates as a medical technology company in Sweden and internationally. The company manufactures and sells POC-Analyzer, a reader with a built-in software, analyzes the color change that occurs in the test cassette; and Neo-Bilirubin, a test cassette with a patented filter design that separates the red blood cells from the plasma used in the POC-Analyzer. It also provides a POC test solution for assessing the severity of COVID-19.
Calmark Sweden AB (publ) Fundamentals Summary
| 9C7 fundamental statistics | |
|---|---|
| Market cap | €11.03m |
| Earnings (TTM) | -€1.99m |
| Revenue (TTM) | €12.16k |
1.9x
P/S Ratio0.0x
P/E RatioIs 9C7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9C7 income statement (TTM) | |
|---|---|
| Revenue | SEK 136.00k |
| Cost of Revenue | SEK 1.07m |
| Gross Profit | -SEK 938.00k |
| Other Expenses | SEK 21.30m |
| Earnings | -SEK 22.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | -689.71% |
| Net Profit Margin | -16,348.53% |
| Debt/Equity Ratio | 0% |
How did 9C7 perform over the long term?
See historical performance and comparison